Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Adalimumab

Brand: Humira®
NICE TA: 460
Indication: Treating non-infectious uveitis (NICE TA460)
Disease category: Eye
Commissioning responsibility: NHS England
PbR excluded: Yes

Background

Adalimumab is recommended as an option for treating non-infectious uveitis in the posterior segment of the eye in adults with inadequate response to corticosteroids, only if there is:

•active disease (that is, current inflammation in the eye) and
•inadequate response or intolerance to immunosuppressants and
•systemic disease or both eyes are affected (or 1 eye is affected if the second eye has poor visual acuity) and
•worsening vision with a high risk of blindness (for example, risk of blindness that is similar to that seen in people with macular oedema).

Stop adalimumab for non-infectious uveitis in the posterior segment of the eye in adults with inadequate response to corticosteroids if there is 1 of the following:

•new active inflammatory chorioretinal or inflammatory retinal vascular lesions, or both or
•a 2‑step increase in vitreous haze or anterior chamber cell grade or
•worsening of best corrected visual acuity by 3 or more lines or 15 letters.

Recommendation

LMMG recommendation: Red
Click here to find the definitions for the colour classifications

Reason for decision:  Specialist medicine

Supporting documents:

NICE TA460 - Adalimumab and dexamethasone for treating non-infectious uveitis

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red